FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SUSVIMO, Genentech's port delivery system for ranibizumab, expanding its use for the treatment of neovascular ag…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• SUSVIMO (Ranibizumab)

Snippet

SUPPL AP for SUSVIMO (RANIBIZUMAB)